About US

We are inspired by the Arctic Tern, a small, nimble seabird that migrates a greater distance than any other species of bird.


“A deep commitment to the needs of patients in underserved markets is central to everything we do, and every decision we make at Terns.”

Weidong Zhong, Ph.D.
President and CEO



Presence in China

Our cross-border structure begins with a world-class clinical development team based in Shanghai, China. This combined with expertise in disease biology, medicinal chemistry, and global clinical development give us a core competency and advantage in pursuing global strategies to treat NASH and cancer.

Liver Disease

Terns is developing a pipeline of novel therapies that target chronic liver diseases such as non-alcoholic steatohepatitis (NASH), liver fibrosis and hepatocellular carcinoma. We are taking a 360-degree approach to developing rational combination therapies that address large unmet medical needs.


A highly experienced leadership team came together with an understanding that certain growing health problems like liver disease are far outpacing drug development, particularly in underserved markets like China. We are based in Foster City, California and Shanghai, China, giving us access to two sets of regional talent, which we believe will enable us to develop and commercialize novel therapies more rapidly.


Weidong Zhong, Ph.D.
President and Chief Executive Officer

Erin Quirk, M.D.
Chief Medical Officer

Ankang Li, Ph.D.
Chief Financial Officer

Randall Halcomb, Ph.D.
Senior Vice President, Chemistry and
Early Development

Martijn Fenaux Ph.D.
Vice President, Biology

Matt Duan, Ph.D.
Vice President, Pharmaceutical Development